Myelofibrotic and leukemic transformation in 2016 WHO-defined Philadelphia-negative myeloproliferative neoplasm

Abstract

Background: Information on myelofibrotic and leukemic transformations in Korean Philadelphia chromosome-negative myeloproliferative neoplasms (Ph  MPNs) is limited.Methods: This study retrospectively analyzed transformations in patients diagnosed with essential thrombocythemia (ET), polycythemia vera (PV) prefibrotic/early primary myelofibrosis (pre-PMF), or overt primary myelofibrosis (PMF) based on the 2016 World Health Organization criteria between

Effects of tertiary palliative care on the pattern of end‐of‐life care in patients with hematologic malignancies in Korea

“…Symptoms and laboratory findings on admission were also recorded. HM diagnosis was categorized into acute leukemia, 16 myelodysplastic syndrome (MDS), lymphoma, 17 multiple myeloma (MM), and others (including myeloproliferative neoplasm) 18 . The initial disease risk was defined according to disease subtype and cytogenetic findings 19 .…”

“…HM diagnosis was categorized into acute leukemia, 16 myelodysplastic syndrome (MDS), lymphoma, 17 multiple myeloma (MM), and others (including myeloproliferative neoplasm). 18 The initial disease risk was defined according to disease subtype and cytogenetic findings. 19 Disease status at admission was defined as follows: unevaluable, indicating that the response could not be assessed owing to incomplete or ongoing first-line therapy or ongoing diagnostic procedures; controlled, denoting complete remission in cases of leukemia and MDS or complete remission and partial remission in cases of lymphoma and MM; and uncontrolled, encompassing other cases, including progression to acute leukemia.…”

Cancer-associated fibroblasts in acute leukemia

“…3 CAFs in the BMM of leukemia chronic asymptomatic state to acute leukemic transformation, and possibly a preleukemic state (126,127). Most forms of secondary MF collaborate with myeloproliferative neoplasms (MPN) and chronic myeloid leukemia (CML).…”

“…Now, myelofibrosis (MF) is defined as a clonal hematopoietic BCR-ABL-negative myeloproliferative neoplasm characterized by BM fibrosis, extramedullary hematopoiesis, megakaryocytic hyperplasia, and constitutional symptoms ( 126 ). MF may be primary or secondary with a heterogeneous clinical course, ranging from a chronic asymptomatic state to acute leukemic transformation, and possibly a preleukemic state ( 126 , 127 ). Most forms of secondary MF collaborate with myeloproliferative neoplasms (MPN) and chronic myeloid leukemia (CML).…”

Acquired von willebrand syndrome in patients with philadelphia-negative myeloproliferative neoplasm

“…Philadelphia chromosome-negative myeloproliferative neoplasms (Ph -MPNs) include essential thrombocythemia (ET), polycythemia vera (PV), prefibrotic primary myelofibrosis (pre-PMF) and overt primary myelofibrosis (PMF). These clonal hematologic disorders are characterized by thrombotic vascular events [1] and myelofibrotic and leukemic transformations [2]. In addition to thrombosis, hemor-rhagic vascular events often occur in these patients, and some cases are associated with acquired von Willebrand syndrome (AVWS) [3].…”